Synthetic lethal therapies for cancer: what's next after PARP inhibitors?

被引：304

作者：

Ashworth, Alan ^{[1
]}

Lord, Christopher J. ^{[2
,3
]}

机构：

[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA

[2] Inst Canc Res, CRUK Gene Funct Lab, London, England

[3] Inst Canc Res, Breast Canc, London, England

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2018年 / 15卷 / 09期

关键词：

TARGETING DNA-REPAIR; RENAL-CELL CARCINOMA; MYC-DRIVEN CANCER; POLY(ADP-RIBOSE) POLYMERASE; OVARIAN-CANCER; BREAST-CANCER; HOMOLOGOUS-RECOMBINATION; THERAPEUTIC STRATEGY; COLLATERAL LETHALITY; COMBINATION THERAPY;

D O I：

10.1038/s41571-018-0055-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The genetic concept of synthetic lethality has now been validated clinically through the demonstrated efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of cancers in individuals with germline loss-of-function mutations in either BRCA1 or BRCA2. Three different PARP inhibitors have now been approved for the treatment of patients with BRCA-mutant ovarian cancer and one for those with BRCA-mutant breast cancer; these agents have also shown promising results in patients with BRCA-mutant prostate cancer. Here, we describe a number of other synthetic lethal interactions that have been discovered in cancer. We discuss some of the underlying principles that might increase the likelihood of clinical efficacy and how new computational and experimental approaches are now facilitating the discovery and validation of synthetic lethal interactions. Finally, we make suggestions on possible future directions and challenges facing researchers in this field.

引用

页码：564 / 576

页数：13

共 137 条

[1] Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers [J].

Aguirre, Andrew J. ;

Hahn, William C. .

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2018, 8 (08)

[2] Genetic Interactions in Cancer Progression and Treatment [J].

Ashworth, Alan ;

Lord, Christopher J. ;

Reis-Filho, Jorge S. .

CELL, 2011, 145 (01) :30-38

[3] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].

Audeh, M. William ;

Carmichael, James ;

Penson, Richard T. ;

Friedlander, Michael ;

Powell, Bethan ;

Bell-McGuinn, Katherine M. ;

Scott, Clare ;

Weitzel, Jeffrey N. ;

Oaknin, Ana ;

Loman, Niklas ;

Lu, Karen ;

Schmutzler, Rita K. ;

Matulonis, Ursula ;

Wickens, Mark ;

Tutt, Andrew .

LANCET, 2010, 376 (9737) :245-251

[4] Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 [J].

Barbie, David A. ;

Tamayo, Pablo ;

Boehm, Jesse S. ;

Kim, So Young ;

Moody, Susan E. ;

Dunn, Ian F. ;

Schinzel, Anna C. ;

Sandy, Peter ;

Meylan, Etienne ;

Scholl, Claudia ;

Froehling, Stefan ;

Chan, Edmond M. ;

Sos, Martin L. ;

Michel, Kathrin ;

Mermel, Craig ;

Silver, Serena J. ;

Weir, Barbara A. ;

Reiling, Jan H. ;

Sheng, Qing ;

Gupta, Piyush B. ;

Wadlow, Raymond C. ;

Le, Hanh ;

Hoersch, Sebastian ;

Wittner, Ben S. ;

Ramaswamy, Sridhar ;

Livingston, David M. ;

Sabatini, David M. ;

Meyerson, Matthew ;

Thomas, Roman K. ;

Lander, Eric S. ;

Mesirov, Jill P. ;

Root, David E. ;

Gilliland, D. Gary ;

Jacks, Tyler ;

Hahn, William C. .

NATURE, 2009, 462 (7269) :108-U122

[5] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[6] Sustained E2F-Dependent Transcription Is a Key Mechanism to Prevent Replication-Stress-Induced DNA Damage [J].

Bertoli, Cosetta ;

Herlihy, Anna E. ;

Pennycook, Betheney R. ;

Kriston-Vizi, Janos ;

de Bruin, Robertus A. M. .

CELL REPORTS, 2016, 15 (07) :1412-1422

[7] ARID1A-mutated ovarian cancers depend on HDAC6 activity [J].

Bitler, Benjamin G. ;

Wu, Shuai ;

Park, Pyoung Hwa ;

Hai, Yang ;

Aird, Katherine M. ;

Wang, Yemin ;

Zhai, Yali ;

Kossenkov, Andrew V. ;

Vara-Ailor, Ana ;

Rauscher, Frank J., III ;

Zou, Weiping ;

Speicher, David W. ;

Huntsman, David G. ;

Conejo-Garcia, Jose R. ;

Cho, Kathleen R. ;

Christianson, David W. ;

Zhang, Rugang .

NATURE CELL BIOLOGY, 2017, 19 (08) :962-+

[8] Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers [J].

Bitler, Benjamin G. ;

Aird, Katherine M. ;

Garipov, Azat ;

Li, Hua ;

Amatangelo, Michael ;

Kossenkov, Andrew V. ;

Schultz, David C. ;

Liu, Qin ;

Shih, Ie-Ming ;

Conejo-Garcia, Jose R. ;

Speicher, David W. ;

Zhang, Rugang .

NATURE MEDICINE, 2015, 21 (03) :231-+

[9] The origin of variations in sexual and sex-limited characters [J].

Bridges, CB .

AMERICAN NATURALIST, 1922, 56 :51-63

[10] Targeting DNA Repair in Cancer : Beyond PARP Inhibitors [J].

Brown, Jessica S. ;

O'Carrigan, Brent ;

Jackson, Stephen P. ;

Yap, Timothy A. .

CANCER DISCOVERY, 2017, 7 (01) :20-37

← 1 2 3 4 5 6 7 8 9 10 →